Novo Nordisk A/s

Novo Nordisk Healthcare Ag

Christine Bruun Schiødt

Florencio Zaragoza Dörwald

Helle Fabricius Wöldike

Ole Hvilsted Olsen

Thomas Kruse

Thomas Kruse Hansen

Jens Breinholt

Bernd Peschke

Kjeld Madsen

Helle Demuth

Anne Worsaae

Peter Thygesen

Leif Nørskov-Lauritsen

Helle Wöldike

The invention relates to methods for increasing the plasma half-life of a molecule, such as human growth hormone, comprising covalently linking the molecule to a heterocyclic carboxylic acid bioisostere.

Polypeptide protracting tags

The present invention relates to stable growth hormone (GH) compounds, which through the introduction of cysteine residues have disulphide bridges, which make the compounds resistant to proteolytic degradation.

Stable growth hormone compounds resistant to proteolytic degradation

The invention provides derivatives of IL-21 or variants thereof, methods of producing such variants, new variants of IL-21, and various methods of using such molecules.

IL-21 derivatives and variants

Plasmid comprising a DNA tag encoding a peptide tag of the sequence MX(XX)wherein Xrepresents K, R or H; Xrepresents A, G, H, M, S or T; Xrepresents K, R, H, A, Q or V; n represents an integer of 1 or larger; and wherein said DNA is operably-linked to a promoter sequence are provided.

[object Object]

Growing community of inventors

Brønshøj, Denmark

Christine Bruun Schiødt